Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 3
Submit an article Journal homepage
2,162
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma

Myung Sun Kima Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Titas Banerjeea Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAORCID Iconhttps://orcid.org/0000-0001-8077-7888View further author information
ORCID Icon,
Andy Chena Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Alexey Danilovb City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Renee MacKinnona Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Bria Thurlowa Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Sujata Thakurtaa Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Kirsten Orandb City of Hope National Medical Center, Duarte, CA, USAView further author information
,
Catherine Degnina Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Byung Parka Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
&
Stephen E. Spurgeona Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USACorrespondence[email protected]
View further author information
 show all
Pages 722-724 | Received 15 Dec 2021, Accepted 15 Feb 2022, Published online: 09 Mar 2022

References

  • Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745.
  • Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516.
  • Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667.
  • Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. Clin Cancer Res. 2020;26(16):4216–4224.
  • Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of Mantle-Cell lymphoma. N Engl J Med. 2018;378(13):1211–1223.
  • Jain P, Zhao S, Lee HJ, et al. Ibrutinib with rituximab in First-Line treatment of older patients with mantle cell lymphoma. J Clin Oncol. 2022;40(2):202–212. JCO.21.01797.
  • Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56.
  • Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109–e116.
  • Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in Mantle-Cell lymphoma. N Engl J Med. 2017;377(13):1250–1260.
  • Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–531.
  • Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110.
  • Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344.
  • Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2912–2919.
  • Albertsson-Lindblad A, Freiburghaus C, Jerkeman M, et al. Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. Exp Hematol Oncol. 2019;8:16.
  • Cheson BD, Fisher RI, Barrington SF, et al.; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of hodgkin and Non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3067.
  • Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005;61(2):540–545.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.